Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies reported strong Q3 2022 results, with revenue of $1.72 billion, reflecting an 8% year-over-year increase. GAAP net income reached $329 million or $1.10 EPS, a 28% increase from last year. Non-GAAP net income was $401 million with $1.34 EPS, up 22%. The company has raised its full-year revenue guidance to $6.750-$6.775 billion, indicating 6.8%-7.2% growth. Expected Q4 revenue is $1.750-$1.775 billion with non-GAAP EPS of $1.38-$1.40.
Agilent Technologies Inc. (NYSE: A) has acquired Polymer Standards Service GmbH (PSS) to enhance its offerings in polymer characterization. PSS specializes in gel permeation chromatography (GPC) and size exclusion chromatography (SEC), crucial for analyzing macromolecules. This acquisition aims to expand Agilent's product portfolio, particularly in chemical and biopharmaceutical industries. The integration will leverage Agilent’s global reach to broaden the use of PSS's technologies and products. Financial terms of the acquisition have not been disclosed.
Agilent Technologies (NYSE: A) has awarded the Agilent Thought Leader Award to Professor Gerhardt Attard from University College London for his groundbreaking research in prostate cancer using innovative liquid biopsy technologies. The award will support the identification of biomarkers related to cancer progression through analysis of circulating tumor DNA. Professor Attard expressed excitement about the potential of his research to enhance diagnostic tools for cancer treatment. Agilent's commitment to funding such research highlights its ongoing investment in advancing cancer genomics and diagnostics.
Agilent Technologies (NYSE: A) announced that Stefanos Nikolaidis, an Assistant Professor at USC Viterbi School of Engineering, received the 2022 Early Career Professor Award for his contributions to AI and Machine Vision in manufacturing. This award emphasizes Agilent's commitment to innovative technology in manufacturing, particularly in developing intuitive collaborative robots (cobots). Dr. Nikolaidis' research aims to enhance manufacturing capabilities and ensure timely delivery of high-quality scientific instruments. The company generated $6.32 billion in revenue in fiscal 2021.
Summary not available.
Agilent Technologies (NYSE: A) has been recognized with a Top Project award for its Certified Pre-Owned Instruments Program, which reduces waste significantly. The program allows lab customers to trade in used instruments for cash or new purchases, promoting sustainability. In fiscal 2021, Agilent bought back over 900 used instruments and sold more than 3,500 certified pre-owned instruments. The initiative aligns with Agilent's commitment to net-zero emissions by 2050 and enhances their Environmental, Social and Governance (ESG) efforts.
Agilent Technologies Inc. (NYSE: A) will release its third-quarter financial results for fiscal 2022 after market close on August 16, 2022. A live webcast of the investor conference call will occur at 1:30 p.m. Pacific time on the same day. Agilent is a leader in life sciences and diagnostics, generating $6.32 billion in revenue in fiscal 2021, employing over 17,000 people globally. Investors can access the webcast via the company's investor relations website, with a replay available for 90 days.
Halo Labs, a company specializing in life science instrumentation, has successfully raised $6M in series C financing, led by Agilent Technologies. This funding will be utilized to enhance the commercialization of the Aura™ platform, expand manufacturing capacity, and develop new products targeting pharmaceutical researchers. CEO Rick Gordon expressed that this funding reflects the success of their aggressive growth strategy, noting that their instruments are now widely adopted by major biopharmaceutical firms. The Aura platform combines multiple assays into one instrument, expediting the development of new therapies.
Agilent Technologies Inc. (NYSE: A) has received FDA approval for its content uniformity (CU) testing method utilizing the TRS100 Raman quantitative pharmaceutical analysis system. This approval, which specifically pertains to Teva Pharmaceutical Industries Ltd, marks a significant milestone for Agilent. The TRS100 system facilitates rapid analysis of active pharmaceutical ingredients (API) in tablets or capsules, enhancing quality control processes. The method’s FDA endorsement reduces risks related to adopting this technology, encouraging its implementation in manufacturing and quality control.
Agilent Technologies (NYSE: A) announced that its customer demonstration laboratory in Waldbronn, Germany, achieved the highest level of Green Lab Certification, indicating strong sustainability practices. This certification, recognized by the UN Race to Zero campaign, highlights Agilent's commitment to environmentally friendly operations in energy, water use, and waste management. This facility is the first of its kind for Agilent to receive this certification, with plans for additional labs to follow. The move aligns with Agilent's broader goals of achieving net-zero greenhouse gas emissions by 2050.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
